More Post from the Author
- OMRON Healthcare dona 4.000 monitores de presin arterial y avanza en la deteccin de fibrilacin auricular
- OMRON Healthcare spendet 4.000 Blutdruckmessgerte und verbessert AFib-Screening mit AI-basierter Intellisense AFib-Technologie
- Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression
- Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update
- Hydro-Tail - The New Standard In Silica Dust Suppression
Charter to Participate in Morgan Stanley Technology, Media & Telecom Conference

STAMFORD, Conn., Feb. 25, 2025 /PRNewswire/ -- Charter Communications, Inc. (NASDAQ: CHTR) (along with its subsidiaries, "Charter") today announced that Christopher Winfrey, President and Chief Executive Officer, will participate in the Morgan Stanley Technology, Media & Telecom Conference in San Francisco, California on Monday, March 3, 2025. Mr. Winfrey's remarks are scheduled to begin at 10:00 a.m. PT (1:00 p.m. ET).
A live webcast of the event can be accessed on Charter's investor relations website, ir.charter.com. Following the live broadcast, the webcast will be archived at ir.charter.com.
About Spectrum
Spectrum is a suite of advanced communications services offered by Charter Communications, Inc. (NASDAQ:CHTR), a leading broadband connectivitycompany and cable operator with services available to nearly 57 million homes and businesses in 41 states. Over an advanced communications network, the Company offers a full range of state-of-the-art residential and business services including Spectrum Internet, TV, Mobile and Voice.
More information about Charter can be found at corporate.charter.com.
SOURCE Charter Communications, Inc.

More Post from the Author
- OMRON Healthcare dona 4.000 monitores de presin arterial y avanza en la deteccin de fibrilacin auricular
- OMRON Healthcare spendet 4.000 Blutdruckmessgerte und verbessert AFib-Screening mit AI-basierter Intellisense AFib-Technologie
- Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression
- Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update
- Hydro-Tail - The New Standard In Silica Dust Suppression